SENIOR MANAGEMENT TEAM
Dr. Glover is an accomplished life sciences professional, with extensive strategic, financial and operational experience in the biotechnology sector, evidenced by demonstrable value creation and successful outcomes. Previously, Dr. Glover served as the President and Chief Executive Officer at YM BioSciences Inc., a publically traded oncology drug development company acquired by Gilead Sciences Inc. in February 2013. YM’s lead drug candidate, momelotinib, was an orally administered JAK inhibitor being developed for the treatment of myelofibrosis and other hematological disorders. Prior to that, Dr. Glover served as the President and Chief Executive Officer of Viventia Bio Inc., a publically traded biopharmaceutical company focused on the development of monoclonal antibody technologies. Dr. Glover also previously served as an investment manager for MDS Capital, a life sciences venture capital firm. He currently serves on the board of directors of MEI Pharma Inc., a company developing novel therapies for hematology and oncology. Dr. Glover holds a BSc (Hons) in chemistry from the University of East Anglia, a MSc in chemistry from the University of British Columbia and a PhD in chemistry from Simon Fraser University.
Dr. You, Chief Business & Strategy Officer & Head of Commercial, leads the Company’s strategic and transactional business and commercial efforts. Previously, Dr. You served as the Chief Business Officer of Aragon Pharmaceuticals, a private oncology drug discovery and development company, where she was responsible for finance, operations, HR and business development. During her tenure, she helped raise $90M in two successful rounds of financing for the company, and led the business development process resulting in the $1B acquisition of Aragon Pharmaceuticals by Johnson & Johnson for an upfront payment of $650M and $350M in contingent milestones. Prior to Aragon, Angie served as Chief Business Officer at a number of life science companies including Synosia Therapeutics and Ren Pharmaceuticals. She also previously served as Vice President at Venrock, a venture capital firm, and as a consultant at McKinsey Consulting. Dr. You holds an AB and PhD from Harvard University.
Dr. Klencke is an accomplished oncology drug developer with a demonstrable track record of success, having made substantial contributions to the development and approval of numerous significant oncology products. Previously, Dr. Klencke served as the Senior Vice President, Development at Onyx Pharmaceuticals, a subsidiary of Amgen Inc., from January 2011 to June 2015, and prior to that was the Group Medical Director in Product Development, Oncology at Genentech, Inc., having joined the company in July 2003. In this period, she led a variety of oncology programs including those for Kyprolis (carfilzomib), Kadcyla (ado-trastuzumab emtansine), Avastin (bevacizumab), and Tarceva (erlotinib). Prior to that, Dr. Klencke served as the Medical Director at Chiron Corporation, a biotechnology company later acquired by Novartis International AG, and as an Assistant Professor of Medicine at the University of California, San Francisco Medical Center. Dr. Klencke holds a BS from Indiana University and an MD from the University of California, Davis.
Dr. Mark Kowalski has extensive experience in Phase I through Phase IV drug development and clinical trial execution in a wide variety of therapeutic areas, including oncology. Dr. Kowalski was most recently the Chief Medical Officer and Senior Vice President at Arbutus Biopharma, a biotechnology company devoted to discovering and developing a cure for chronic Hepatitis B. Prior to that, he held the same position at Tekmira, a biopharmaceutical company focused on developing therapeutics based on RNA interference utilizing lipid nanoparticle delivery technology in oncology, infectious disease, metabolic and other clinical indications. Prior to joining Tekmira, Dr. Kowalski worked in the oncology and inflammation therapeutic area at Gilead Sciences, Inc. following Gilead’s $510-million acquisition of YM BioSciences Inc., at which Dr. Kowalski had been CMO and Vice President of Regulatory Affairs. Dr. Kowalski’s experience also encompasses being the CMO and Vice President of Medical/Regulatory Affairs at Viventia Biotechnologies Inc. and the Senior Director of Medical Affairs at AAIPharma Inc. Dr. Kowalski holds a B.A. from Rutgers University and an M.D. and Ph.D. from the University of Kansas School of Medicine. He completed his postgraduate training in internal medicine and infectious diseases at Duke University and Harvard Medical School and is Board certified in both.
Sukhi Jagpal joined Sierra Oncology in February 2015 as our Chief Financial Officer (CFO). Previously, Sukhi was the CFO of QLT Inc., a dual-listed biotechnology company also based in Vancouver (Nasdaq:QLTI; TSX:QLT). During his tenure, he assisted QLT in developing its finance capabilities to deal with several growth phases which included raising capital and completing several acquisitions. Prior to joining QLT in 2003, Sukhi held senior finance positions with Pivotal Corporation, 360networks inc., and KPMG LLP. Sukhi is a Chartered Accountant, a Chartered Business Valuator, and holds a MBA from the S.C. Johnson Graduate School of Management, Cornell University and a MBA from Queen’s University, Kingston.
Dr. Keith Anderson, Senior Vice President, Technical Operations, leads the development of the Company’s strategic manufacturing and supply chain strategy with a broad focus on building a full-fledged, commercial-scale operation. Dr. Anderson is a seasoned pharmaceutical development executive with a proven track-record of developing and commercializing successful products. His 20-year career in pharmaceutical research included positions at Ligand Pharmaceuticals and Ocera Therapeutics, where he was Chief Operating and Chief Scientific Officer. Prior to joining Sierra Oncology, Dr. Anderson held the role of Vice President, Manufacturing at Seragon Pharmaceuticals, where he led CMC and supply chain activities until the company was acquired by Genentech/Roche. He holds a PhD in Pharmaceutical Sciences from the University of Alberta.
Ms. Chapman, Senior Vice President, Clinical Operations, has corporate accountability for the overall operational deployment of clinical studies. Previously, Wendy was the Senior Portfolio Director at PAREXEL International where she was the senior point of contact for all issues related to the financial and operational execution of Phase II-IV global clinical trials for one of PAREXEL’s largest Strategic Alliance Partners. Previously, Ms. Chapman was the Vice President of Clinical Operations at YM Biosciences Inc., where she was responsible for the development and management of Clinical Operations which included Project Management, Clinical Monitoring, Clinical Supply Management and Data Management of Phase I-III clinical trials in myelofibrosis and various solid tumor indications. Wendy has more than 25 years of experience in clinical drug development at several pharmaceutical and contract research organizations in Canada and the U.S., including Viventia Biotech, AAI Pharma, Bayer Inc., AstraZeneca and MDS Pharma Services.
Ms. Gardiner is responsible for Human Resources at Sierra Oncology. Previously, Diane served as Vice President of Human Resources for Tekmira Pharmaceuticals. Before joining Tekmira, she held the positions of Head of Human Resources for Aquinox Pharmaceuticals, Vice President of Human Resources for The Centre for Drug Research and Development, and Director of Human Resources for AnorMED Inc. Earlier in her career Diane held various Human Resources leadership roles, including Director, Human Resources for MDS Metro Laboratories. Diane holds a Bachelor of Business Administration from Simon Fraser University and is a member of the BC Human Resource Management Association as well as the BC HR Tech Group.
Dr. Christian Hassig, Senior Vice President, Research, leads the Company’s strategic research activities from discovery research through to early candidate development. Dr. Hassig has a strong record of accomplishments in both discovery research and preclinical development across multiple therapeutic areas and has pioneered lead discovery projects against innovative targets in oncology, from target discovery through to IND. Dr. Hassig maintains an adjunct faculty appointment at The Scripps Research Institute in La Jolla. Prior to joining Sierra Oncology, he was formerly the Vice President of Drug Discovery at the Sanford Burnham Prebys Medical Discovery Institute, having previously served as its Director of Drug Discovery from 2010 to 2015. Prior to this, Dr. Hassig served as the Department Head of Biology at Kalypsys, Inc., a privately owned biopharmaceutical company specializing in small molecule drug discovery and development, and held multiple roles within its Biology and Lead Discovery departments. Dr. Hassig holds a B.A. in Chemistry/Biochemistry from the University of California, San Diego, and a Ph.D. from Harvard University. He completed a Postdoctoral Fellowship at the University of California, Berkeley.
Ms. Lovejoy is responsible for Regulatory Affairs and Quality management at Sierra Oncology. Most recently, Chandra was the Vice President of Global Regulatory Affairs at Endocyte, and prior to that she held a leadership role in Regulatory Affairs at Genentech, primarily on the Avastin program. Chandra brings experience driving cutting-edge global regulatory strategy and leading cross-functional team activities including new IND submissions, implementation and conduct of global clinical trials, successful negotiations with both FDA and European health authorities regarding complex pivotal trials, and the submission and review of marketing applications. Ms. Lovejoy holds a BS from the University of San Francisco and an MS from San Diego State University.
Ms. McCann is responsible for program management at Sierra Oncology. Emma was formerly Sr. Director, Program Management at YM BioSciences Inc., where she had a critical role within the organization focused on the progression of the company’s lead drug through a myelofibrosis clinical development program. Following the acquisition of YM by Gilead Sciences, Inc., her leadership of transitional activities led to a seamless transfer of key corporate assets allowing for execution of ongoing development plans with minimal overall timeline impact. Emma holds a BSc (Hons) in Bio-Medical Science from The University of Guelph, Ontario.
Dr. Gregg Smith leads nonclinical development activities, with a focus on supporting the Company’s ongoing clinical programs for SRA737 and SRA141 and expanding the Company’s pipeline of oncology drug candidates. Previously, Dr. Smith served as Vice President Drug Development at Cytopia, a public Australian company, continuing in that role at YM BioSciences Inc., following its merger with Cytopia. He also served as a Research and Development Executive at Gilead Sciences Inc., after its acquisition of YM. He has also held senior drug development operations roles at several other Australian biotechnology companies. Dr. Smith holds Pharmacy (Honours) and PhD degrees from the University of Queensland (Brisbane, Australia) and an MBA from Latrobe University in Melbourne.